State Street Corp Buys 515,179 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

State Street Corp grew its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 68.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,271,609 shares of the specialty pharmaceutical company’s stock after purchasing an additional 515,179 shares during the period. State Street Corp owned approximately 2.94% of KalVista Pharmaceuticals worth $14,725,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in KalVista Pharmaceuticals by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,600 shares of the specialty pharmaceutical company’s stock valued at $1,597,000 after purchasing an additional 23,547 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of KalVista Pharmaceuticals during the second quarter worth $25,000. Rhumbline Advisers raised its stake in KalVista Pharmaceuticals by 12.5% in the 2nd quarter. Rhumbline Advisers now owns 53,228 shares of the specialty pharmaceutical company’s stock worth $627,000 after purchasing an additional 5,908 shares in the last quarter. ClariVest Asset Management LLC raised its position in shares of KalVista Pharmaceuticals by 2.8% in the second quarter. ClariVest Asset Management LLC now owns 57,096 shares of the specialty pharmaceutical company’s stock valued at $673,000 after buying an additional 1,535 shares in the last quarter. Finally, Nicholas Investment Partners LP lifted its position in shares of KalVista Pharmaceuticals by 0.9% during the 2nd quarter. Nicholas Investment Partners LP now owns 184,358 shares of the specialty pharmaceutical company’s stock valued at $2,172,000 after acquiring an additional 1,714 shares during the period.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 8,077 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the completion of the transaction, the insider now owns 94,199 shares of the company’s stock, valued at approximately $872,282.74. The trade was a 7.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $9.26, for a total transaction of $133,344.00. Following the sale, the chief executive officer now owns 266,598 shares of the company’s stock, valued at approximately $2,468,697.48. The trade was a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 32,291 shares of company stock valued at $304,086 in the last 90 days. 10.50% of the stock is currently owned by company insiders.

KalVista Pharmaceuticals Stock Down 0.8 %

KALV opened at $8.76 on Wednesday. The stock has a market cap of $432.90 million, a price-to-earnings ratio of -2.41 and a beta of 0.85. The company’s 50-day moving average price is $10.25 and its two-hundred day moving average price is $11.59. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.97 and a twelve month high of $16.88.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on KALV. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, December 6th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday, December 9th. Bank of America initiated coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).